Patients with advanced skin cancer in England will soon participate in a new mRNA vaccine trial as part of the NHS Cancer Vaccine Launch Pad (CVLP), which aims to accelerate access to innovative treatments. The vaccine, iSCIB1+, helps the immune system recognize and attack cancer cells, potentially preventing recurrences, with trials expected to expand by October. As melanoma cases rise, the NHS continues to prioritize innovative cancer care, with experts emphasizing the transformative potential of these vaccines in saving lives.
